Full-Time
VP – Business Development
Posted on 10/1/2025
Enveda Biosciences
201-500 employees
Biotech drug discovery via high-throughput ML
Compensation Overview
$350k - $400k/yr
Boulder, CO, USA
Remote
 Business & Strategy (1) |
|---|
- 10+ years in the biotech or pharma therapeutics industry, with meaningful time spent in business development, strategy, or corporate development roles
- Demonstrated track record of closing BD transactions across discovery and clinical assets
- Proven ability to lead and manage diligence processes with multiple stakeholders
- Strong scientific fluency - advanced degree (MD, PhD, PharmD, MS) strongly preferred, MBA a plus
- Ability to drive clarity in complex or ambiguous situations
- Strong networks of BD and R&D contacts within the biotech and pharma industry
- A blend of curiosity, agency, and high EQ - youre a trusted leader and collaborator
- Experience leading people and putting in place the systems and processes to scale BD activities
- Lead and drive growth by sourcing, shaping, and negotiating partnerships, collaborations, and other business development opportunities aligned with Envedas strategy
- Oversee the full deal lifecycle, from triage and prioritization through diligence, negotiation, and close ensuring processes are efficient, rigorous, and decision-ready
- Lead preparations of data packages, analyses, and materials to support deal activities
- Guide partnering strategy in collaboration with key internal stakeholders
- Maintain a forward view of the market, integrating competitive intelligence, scientific trends, and partner feedback into actionable insights for leadership
- Represent Enveda at key conferences, investor meetings, and industry events
- Strengthen internal BD capabilities by building processes and systems
- MBA is a plus
- Advanced degree (MD, PhD, PharmD, MS) strongly preferred
Enveda Biosciences focuses on drug discovery by tapping into the natural world’s largely uncharted chemical space. It uses a proprietary platform to run high-throughput experiments that generate a comprehensive dataset of small molecules, analyzing chemical structure, biological activity, and organ distribution to rapidly identify drug leads. The company integrates machine learning, metabolomics, and robotics to accelerate discovery and move faster from natural compounds to potential medicines. Its main differentiator is a data-enabled, platform-driven approach that combines advanced analytics with automated experimentation to explore natural products at scale, enabling partnerships and licensing deals with healthcare and pharmaceutical companies. Enveda’s goal is to expand the known chemical space of nature and provide a steady pipeline of promising drug candidates to its clients.
Company Size
201-500
Company Stage
Series D
Total Funding
$534.8M
Headquarters
Boulder, Colorado
Founded
2019
Simplify's Take
What believers are saying
- Raised $150M Series D in 2025, reaching $517M total funding and unicorn status.
- Three clinical-stage assets in eczema, asthma, obesity with $20B sales potential.
- Appointed Christopher Porter SVP Clinical and Jason Kim CFO in 2024-2025.
What critics are saying
- ENV-294 Phase 1b fails efficacy in atopic dermatitis by mid-2026, burns cash.
- Insilico’s INS018_055 Phase 2 success steals Sanofi partnerships in 12 months.
- FDA holds obesity IND in Q2 2026 over metabolite toxicity in preclinical data.
What makes Enveda Biosciences unique
- Enveda decodes natural chemical biodiversity using AI, mass spectrometry, and robotics.
- Platform discovers drugs 4x faster at 1/10th cost versus traditional pharma.
- Translates medicinal plant molecules into therapies for inflammation, fibrosis, pain.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)
Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents
Unlimited paid time off
Flexible work hours and paid parental leave
Company-wide weeklong break to recharge in addition to 8 observed holidays
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↓ -3%Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.
Enveda Biosciences, a Colorado biotech, has secured an additional $150 million for its I&I drug and a wide-ranging pipeline of preclinical assets. The company has grown from an initial $50k "pre, pre-seed" investment to $517 million in total funding, achieving unicorn status.
Enveda Biosciences raised $150 million in Series D funding, doubling its venture capital intake this year. The round was led by Premji Invest and included investors like Kinnevik and Lux Capital. Enveda has begun Phase 1b trials for its lead drug candidate in atopic dermatitis and plans to enter more drugs into human trials soon. The company aims to file investigational new drug applications for other programs over the next year.
AI is helping Corteva Agriscience dramatically accelerate the development of new crop protection products by modeling proteins and molecules with “unprecedented speed and accuracy,” an exec told a congressional subcommittee this morning. Speaking at a House Environment Subcommittee hearing on innovations in agrichemicals, Brian Lutz, PhD, VP agricultural solutions at Corteva, said AI had “revolutionized discovery by allowing us to trade randomness and chance for prediction, specificity and design.”. Predicting the structure of proteins in seconds
Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M